(Q48608880)

English

Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.

scientific article published on 20 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lopinavir/ritonavir

1 reference

based on heuristic

inferred from title

Kiat Ruxrungtham

13

object named as

Kiat Ruxrungtham

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

Bernard Hirschel

11

object named as

Bernard Hirschel

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

Jintanat Ananworanich

14

object named as

Jintanat Ananworanich

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

author name string

Torsak Bunupuradah

1

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Ploenchan Chetchotisakd

2

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Supunnee Jirajariyavej

3

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Victor Valcour

4

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Chureeratana Bowonwattanuwong

5

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Warangkana Munsakul

6

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Virat Klinbuayaem

7

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Wisit Prasithsirikul

8

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Jiratchaya Sophonphan

9

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Apicha Mahanontharit

10

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Sorakij Bhakeecheep

12

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

HIV STAR Study Group

15

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

publication date

20 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

Journal of NeuroVirology

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

18

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

6

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

479-487

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

https://scigraph.springernature.com/pub.10.1007/s13365-012-0127-9

0 references

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Primary, post-primary and non-specific immunoglobulin M responses in HCV infection.

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

The neuropathogenesis of AIDS

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Protease inhibitor monotherapy and the CNS: peace of mind?

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study.

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

The prevalence and incidence of neurocognitive impairment in the HAART era.

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Neuropsychological abnormalities in patients with dementia in CRF 01_AE HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Pathogenesis of HIV in the central nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Screening for cognitive impairment in human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

HIV-associated prospective memory impairment in the laboratory predicts failures on a semi-naturalistic measure of health care compliance

1 reference

https://api.crossref.org/works/10.1007%2FS13365-012-0127-9

21 January 2018

Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/22993101

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir

1 reference

https://pubmed.ncbi.nlm.nih.gov/22993101

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of the Thai Depression Inventory.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22993101

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurologic complications of HIV disease and their treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22993101

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22993101

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Boosted protease inhibitor monotherapy. What have we learnt after seven years of research?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22993101

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13365-012-0127-9

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/22993101

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48608880&oldid=1562729202"